Predicting Outcomes in Idiopathic Pulmonary Fibrosis Using Automated Computed Tomographic Analysis.
Joseph JacobBrian J BartholmaiSrinivasan RajagopalanColine H M van MoorselHendrik W van EsFrouke T van BeekMarjolijn H L StruikMaria KokosiRyoko EgashiraAnne Laure BrunArjun NairSimon L F WalshGary CrossJoseph BarnettAngelo de LauretisEoin P JudgeSujal DesaiRonald KarwoskiSebastien OurselinElisabetta RenzoniToby M MaherAndre AltmannAthol U WellsPublished in: American journal of respiratory and critical care medicine (2019)
Our study has validated a new quantitative CT measure in patients with IPF fulfilling drug trial entry criteria-the VRS score-that outperformed current gold standard measures of outcome. When used for cohort enrichment in an IPF drug trial setting, VRS threshold scores can reduce a required IPF drug trial population size by 25%, thereby limiting prohibitive trial costs. Importantly, VRS scores identify patients in whom antifibrotic medication prolongs life and reduces FVC decline.
Keyphrases
- idiopathic pulmonary fibrosis
- phase iii
- study protocol
- phase ii
- clinical trial
- end stage renal disease
- interstitial lung disease
- chronic kidney disease
- randomized controlled trial
- adverse drug
- newly diagnosed
- computed tomography
- open label
- healthcare
- ejection fraction
- peritoneal dialysis
- magnetic resonance imaging
- type diabetes
- high resolution
- magnetic resonance
- image quality
- high throughput
- drug induced
- patient reported outcomes
- skeletal muscle
- single cell
- double blind
- placebo controlled